Decitabine for acute myeloid leukemia

Expert Review of Anticancer Therapy

Volumn 12, Issue 3, 2012, Pages 299-305

  Marks, Peter W ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute myeloid leukemia; decitabine; DNA methyltransferase inhibitor; elderly

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CLOFARABINE; CYTARABINE; GEMTUZUMAB OZOGAMICIN; LENALIDOMIDE; SAPACITABINE; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; BACTEREMIA; BONE MARROW SUPPRESSION; CANCER INHIBITION; CANCER MORTALITY; CANCER SURVIVAL; CANCER THERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DNA BINDING; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HUMAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PETECHIA; PNEUMONIA; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CLINICAL TRIALS AS TOPIC; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LEUKEMIA, MYELOID, ACUTE; MALE; MAXIMUM TOLERATED DOSE; METHYLTRANSFERASES; MIDDLE AGED; PHARMACOVIGILANCE; REMISSION INDUCTION; RISK ADJUSTMENT; TREATMENT OUTCOME;

EID: 84857879142     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.207     Document Type: Review

References (34)

1. Menzin J, Boulanger L, Karsten V et al. Effects of initial treatment on survival among elderly AML patients: Findings from the SEER-medicare database. ASH Annu. Meet. Abstracts 108, 1973 (2006).
2. Lang K, Earle CC, Foster T, Dixon D, Van Gool R, Menzin J. Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging 22(11), 943-955 (2005).
3. Ditschkowski M, Elmaagacli AH, Trenschel R et al. Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients. Clin. Transplant. 20, 127-131 (2005).
4. Appelbaum FR, Gundacker H, Head DR et al. Age and acute myeloid leukemia. Blood 107, 3481-3485 (2006).
5. Kantarjian H, Ravandi S, O'Brien S et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116, 4422-4429 (2010).
6. Burnett AK, Milligan D, Prentice AG et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109, 1114-1124 (2007).
7. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 358, 1148-1159 (2008).
8. Mund C, Brueckner B, Lyko F. Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: Basic concepts and clinical applications. Epigenetics 1, 7-13 (2006).
9. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100, 2292-2302 (2002).
10. de Lima M, Giralt S, Thall PF et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: A dose and schedule finding study. Cancer 116, 5420-5431 (2010).
11. Baer MR, Gojo I. Novel agents for the treatment of acute myeloid leukemia in the older patient. J. Natl Compr. Canc. Netw. 9, 331-335 (2011).
12. Taksin AL, Legrand O, Raffoux E et al. High efficacy and safety profile of fractionated doses of Myelotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: A prospective study of the alfa group. Leukemia 21, 66-71 (2007).
13. Lavelle D, Chin J, Vaitkus K et al. Oral decitabine reactivates expression of the methylated g-globin gene in Papio anubis. Am. J. Hematol. 82, 981-985 (2007).
14. Pliml J, Sorm F. Synthesis of 2'-deoxy-d-ribofuranosyl-5-azacytosine. Coll. Czeck. Chem. Commun. 29, 2576-2577 (1964).
15. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int. J. Cancer 123, 8-13 (2008).
16. Sorm F, Vesely J. Effect of 5-aza-2'-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. Neoplasma 15, 339-343 (1968).
17. Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA, Di Fiore PP. 5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 64, 922-929 (1984).
18. Bryan J, Kantarjian H, Garcia-Manero G, Jabbour E. Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Expert Opin. Drug Metab. Toxicol. 7(5), 661-672 (2011).
19. Van Groeningen C, Leyva A, O'Brien A et al. Phase 1 and pharmacokinetic study of 5-aza-2'deoxycytidine (NSC 1277716) in cancer patients. Cancer Res. 46, 4831-4836 (1986).
20. Cashen AF, Shah AK, Todt L, Fisher N, DiPerso J. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother. Pharmacol. 61, 759-766 (2008).
21. Daskalakis M, Blagitko-Dorfs N, Hackanson B. Decitabine. Recent Results Cancer Res. 184, 131-157 (2010).
22. Momparler RL, Rivard GE, Gyger M. Clinical trial on 5-aza-2'- deoxycytidine in patients with acute leukemia. Pharmacol. Ther. 30, 277-286 (1985).
23. Petti MC, Mandelli F, Zagonel V et al. Pilot study of 5-aza-2'-deoxycytidine (decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: Preliminary results. Leukemia 7, 36-41 (1993).
24. Kantarjian HM, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a Phase 3 randomized study. Cancer 106, 1794-1803 (2006).
25. Lübbert M, Suciu S, Baila L et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized Phase 3 study of the European organization for research and treatment of cancer leukemia group and the German MDS study group. J. Clin. Oncol. 29, 1-11 (2011).
26. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter Phase 2 study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J. Clin. Oncol. 28, 556-561 (2009).
27. Blum W, Garzon R, Klisovic RB et al. Clinical response and miR-29b predictive significance [sic] in older patients treated with a 10-day schedule of decitabine. Proc. Natl Acad. Sci. 107, 7473-7478 (2010).
28. Ravandi F, Issa JP, Garcia-Manero G et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer 115, 5746-5751 (2009).
29. Thomas XG, Dmoszynska A, Wierbowska A et al. Results from a randomized Phase 3 trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML. J. Clin. Oncol. 29, 420s (2011).
30. Blum W, Klisovic RB, Hackanson B et al. Phase 1 study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J. Clin. Oncol. 25, 3884-3891 (2007).
31. Kirshbaum M, Gojo I, Goldber SL et al. Vorinostat in combination with decitabine for the treatment of relapsed or newly diagnosed acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS): A Phase 1 dose-escalation study. Blood 114, 824 (2009).
32. Ravandi F. Phase 1/2 study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia. J. Clin. Oncol. 29, 440s (2011).
33. Chowdhury S, Seropian S, Marks P. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia. Am. J. Hematol. 84, 599-600 (2009).
34. Vardiman JW, Thiele J, Arber DA. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 114, 237-251 (2009).